Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THEROS study of osimertinib in TKI-resistant EGFR-mutated non-small cell lung cancer
2017-005121-21Phase 2Suspended
- Sponsor
- Universitätsmedizin Essen
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Universitätsmedizin Essen. Primary endpoint: Rate of metabolic response by FDG-PET at end of cycle 1. Started Sep 2018; status: suspended.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-005121-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005121-21.